Yuan Yuan
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and HR+/HER2- metastatic breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as balstilimab or pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer. Giving ivermectin with balstilimab or pembrolizumab may increase the effect of balstilimab or pembrolizumab in shrinking tumors in patients with triple negative breast cancer and HR+/HER2- metastatic breast cancer. The secondary objectives of the study include evaluating the following efficacy outcomes: objective response rate (ORR), progression free survival (PFS), overall survival (OS), duration of response (DOR), clinical benefit rate (CBR), and patients' quality of life (QOL) by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
Patients receive ivermectin orally (PO) once daily (QD) on days 1-3, 8-10, and 15-17. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive balstilimab or pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 90 days and then periodically thereafter.
Inclusion Criteria: * Age: ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) ≤ 1 * Life expectancy \> 3 months * At least one biopsy proven Triple Negative Breast Cancer (TNBC) or HR+/HER2- breast cancer in the metastatic setting. TNBC is defined by ER and PR ≤ 10% and HER2 negative (by IHC or FISH), per ASCO/CAP guidelines. In the case of discordant expression results, eligibility must be discussed and determined at the discretion of the study PI. * Patients must have progressed on 1-2 prior lines of systemic therapy (chemotherapy and/or drug-antibody conjugate) in the metastatic settin…
Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle